Do you want to know more about how Intravacc can help bring your vaccine concept up to proof of concept?
Check our Factsheets, or Vaccsheets as we call them, for more information on our services, products and platforms.
Publications
Vaccsheets
Intravacc - innovating vaccines
Even the most promising vaccines don’t always make it out of the laboratory into large-scale production.
We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines.
How? By bridging the gap between your concept and late stage clinical studies.
Vaccsheet Intravacc
"*" indicates required fields
GMP facilities
At Intravacc we have two GMP facilities on the campus, Intravacc and BuildingX. We offer pilot GMP production of both viral, bacterial and cancer vaccines. A variety of production technologies are available in both single-use or stainless steel bioreactors.
At Intravacc, the GMP cleanrooms (class c) and quality control span 230 sqm. In BuildingX four labs are available for BSL3 activities (165 sqm). Two of these labs can be used for GMP activities.
Through our partnership network we can produce up to 100 million doses of vaccine.
3R research: Replacement, Reduction and Refinement of animal experiments
Intravacc is one of the leading organizations in global 3R research (Reduce, Replace and Refine), with a main focus on Reduction, Replacement and Refinement of animal use in statutory required testing for vaccine batch release.
Conjugate vaccines
Conjugate vaccines have been extremely successful in preventing disease and death caused by bacterial
infections. Moreover, conjugate vaccines have a superb safety record with very few serious adverse events
following immunization. Intravacc has a 20-year track record in designing, developing and characterizing
conjugate vaccines.
A conjugate vaccine is created by covalently attaching a bacterial polysaccharide, which by itself is not able to induce immunological memory, to a protein carrier antigen, thereby eliciting a stronger immunological response to the antigen.
Outer Membrane Vesicles (OMV) platform
A novel approach for vaccines is the use of Outer Membrane Vesicles (OMVs). Gram-negative bacteria naturally release OMVs. OMVs are spherical particles (±20-200 nm) that harbour many bacterial antigens which play a role in establishing the infection and survival of the bacterium within the host.
The strongest asset of OMV vaccines is the native conformation of protective antigens. Intravacc has extensive expertise developing OMV vaccines and uses this as a platform technology for various vaccines.
Vero cell platform technology
The Vero cell line is the most widely used and most reliable cell line in viral vaccine production in terms of quality, yield and safety. At Intravacc, we have been developing viral vaccines using the Vero cell line since 1987.
Intravacc’s cGMP-grade, regulatory approved Vero cell line is currently being used for routine large-scale commercial vaccine manufacturing by clients all over the world.
NEED MORE INFORMATION?
Contact our
specialist
A team of 140+ specialists is at your disposal here in Bilthoven. Contact us to see how we can bring your vaccine concept ready for in-human trials.
Subscribe to our news update
Stay up to date with the latest developments, and be the first to receive our news updates and announcements.
